Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Asset Writedowns and Impairment of $177.4 million for Q4 2025, down 45.85% year-over-year from $327.7 million in Q4 2024, and up 3185.93% quarter-over-quarter from $5.4 million in Q3 2025.
Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Asset Writedowns and Impairment for 5 consecutive years, with $177.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment fell 45.85% year-over-year to $177.4 million; the TTM figure through Dec 2025 stood at $511.0 million (up 55.87% YoY), while the FY2025 annual figure was $183.3 million, down 44.07% from the prior year.
- Asset Writedowns and Impairment advanced to $177.4 million in Q4 2025 per VRNO's latest filing, from $5.4 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $327.7 million in Q4 2024 and bottomed at -$2.2 million in Q4 2022.
- Historically, Asset Writedowns and Impairment has averaged $43.1 million across 5 years, with a median of $510500.0 in 2023.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment tumbled 2468.24% — and 2023, when it slipped 12.02%.
- Verano Holdings' Asset Writedowns and Impairment stood at -$85000.0 in 2021, then slumped by 2468.24% to -$2.2 million in 2022, then jumped by 401.01% to $6.6 million in 2023, then jumped by 4887.05% to $327.7 million in 2024, then sank by 45.85% to $177.4 million in 2025.
- Business Quant data shows VRNO's Asset Writedowns and Impairment at $177.4 million in Q4 2025, $5.4 million in Q3 2025, and $428000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.06 Mn |
| Jun 30, 2026 | 4.06 Mn |
| Dec 31, 2025 | 177.44 Mn |
| Dec 31, 2025 | 177.44 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 428,000.00 |
| Jun 30, 2025 | 428,000.00 |
| Dec 31, 2024 | 327.70 Mn |
| Dec 31, 2024 | 327.70 Mn |
| Mar 31, 2024 | 112,000.00 |
| Mar 31, 2024 | 112,000.00 |
| Sep 30, 2023 | 6.57 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Mar 31, 2023 | 593,000.00 |
| Mar 31, 2023 | 593,000.00 |
| Dec 31, 2022 | -2.18 Mn |
| Dec 31, 2022 | -2.18 Mn |
| Jun 30, 2022 | 342,000.00 |
| Jun 30, 2022 | 342,000.00 |